- Home
- Mea Lung Transplant Therapeutics Market
MEA Lung Transplant Therapeutics Market - Industry Trends and Forecast to 2029
- Published Date: January, 2022 | Report ID: CLS-49 | No of pages: 130 | Format:
The Middle East and Africa lung transplant therapeutics market is projected to register a substantial CAGR of 2.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Middle East and Africa Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (Saudi Arabia, South Africa, Israel, U.A.E., Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Middle East and Africa lung transplant therapeutics market are:
Rising importance of organ donation and transplantation
Government support for organ transplantation
Market Players:
Some of the key market players in the Middle East and Africa lung transplant therapeutics market are listed below:
Bridge to Life Ltd
Viatris Inc.
BioLife Solutions
Pfizer Inc.
F.Hoffmann-La Roche Ltd.
Panacea Biotec Ltd.
Accord-UK Ltd
Novartis AG
Hikma Pharmaceuticals PLC
Dr. Reddys Laboratories Ltd.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTERS FIVE FORCES MODEL
5 INSURANCE AND REIMBURSEMENT - MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET
5.1 U.S.
5.2 EUROPE
5.3 CANADA
5.4 INDIA
6 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS
6.1 REGULATION IN THE U.S.
6.2 REGULATION IN EUROPE
6.3 REGULATION IN NEW ZEALAND
6.4 REGULATION IN AUSTRALIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 INCREASING DRUG APPROVALS
7.2 RESTRAINTS
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE SPENDING
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 IMMUNOSUPPRESSANT DRUGS
9.2.1 BY CLASS
9.2.1.1 CALCINEURIN INHIBITORS
9.2.1.1.1 TACROLIMUS
9.2.1.1.2 CYCLOSPORIN
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS
9.2.1.2.1 MYCOPHENOLATE MOFETIL
9.2.1.2.2 MYCOPHENOLATE SODIUM
9.2.1.2.3 AZATHIOPRINE
9.2.1.3 M-TOR INHIBITOR
9.2.1.3.1 SIROLIMUS
9.2.1.3.2 EVEROLIMUS
9.2.1.4 STEROIDS
9.2.1.4.1 METHYLPREDNISOLONE
9.2.1.4.2 PREDNISONE
9.2.1.5 MONOCLONAL ANTIBODY
9.2.1.5.1 BASILIXIMAB
9.2.1.5.2 MUROMONAB
9.2.1.6 OTHERS
9.2.2 BY DRUG TYPE
9.2.2.1 BRANDED
9.2.2.2 GENERIC
9.2.3 ROUTE OF ADMINISTRATION
9.2.3.1 ORAL ADMINISTRATION
9.2.3.2 PARENTERAL ADMINISTRATION
9.3 ORGAN PRESERVATION PRODUCTS
9.3.1 PERFADEX
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION
9.3.3 LIFOR
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION
9.3.5 RENOGRAF
9.3.6 OTHERS
9.4 TISSUE PRODUCT
9.5 OTHERS
10 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE
10.1 OVERVIEW
10.2 SINGLE-LUNG TRANSPLANT (SLT)
10.3 DOUBLE LUNG TRANSPLANT
10.4 BILATERAL LUNG TRANSPLANT (BLT)
10.5 HEART-LUNG TRANSPLANT
11 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CADAVERIC LUNG TRANSPLANT
12.3 LIVING LUNG TRANSPLANT
13 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 CYSTIC FIBROSIS
13.3 PULMONARY FIBROSIS
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
13.5 INTERSTITIAL PULMONARY FIBROSIS
13.6 PULMONARY HYPERTENSION
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION
13.8 EMPHYSEMA
13.9 SARCOIDOSIS
13.10 SEPTIC LUNG DISEASE
13.11 OTHERS
14 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 TRANSPLANT CENTERS
14.4 SPECIALTY CENTERS
14.5 OTHERS
15 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION
15.1 MIDDLE EAST AND AFRICA
15.1.1 SAUDI ARABIA
15.1.2 SOUTH AFRICA
15.1.3 ISRAEL
15.1.4 UAE
15.1.5 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ASTELLAS PHARMA INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 DR. REDDYS LABORATORIES LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 F.HOFFMANN-LA ROCHE LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 HIKMA PHARMACEUTICALS PLC
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 APOTEX INC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 XVIVO
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ACCORD-UK LTD
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BIOLIFE SOLUTIONS
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.10 BRIDGE TO LIFE LTD
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 DETRAXI, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 DR.FRANZ KOHLER CHEMIE GBMH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 INTAS PHARMACEUTICALS LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 OSE-IMMUNO
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 PANACEA BIOTEC LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 PARAGONIX TECHNOLOGIES, INC
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.17.3.1 PRODUCT LAUNCH
18.17.3.2 PARTNERSHIP
18.18 PFIZER INC.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 VIATRIS, INC
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.20ST CENTURY MEDICINE
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Segmentation
Short Description:
Middle East and Africa Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (Saudi Arabia, South Africa, Israel, U.A.E., Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
A lung transplant is surgery done to remove a diseased lung and replace it with a healthy lung from another person. Lung transplants surgery can be performed on people of almost all ages, from newborns to adults up to age 65 and sometimes even later. A lung transplant is for people who have tried other medications or treatments, but their underlying conditions have not improved sufficiently or worsened over time. Depending on the patient's medical condition, a lung transplant may involve replacing one lung or both. The lungs may be transplanted with a donor's heart in some situations. A lung transplant can significantly improve patient health and quality of life.
Market Segmentation:
The Middle East and Africa lung transplant therapeutics market is categorized into six notable segments based on product, indication, type, technique, patient demographics, and end users.
On the basis of product, the Middle East and Africa lung transplant therapeutics market is segmented into immunosuppressant drugs, organ preservation products, tissue products, and others
On the basis of indication, the Middle East and Africa lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, sarcoidosis, primary pulmonary arterial hypertension, and others
On the basis of type, the Middle East and Africa lung transplant therapeutics market is segmented into cadaveric lung transplantation, and living lung transplantation
On the basis of technique, the Middle East and Africa lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double-lung transplantation
On the basis of patient demographics, the Middle East and Africa lung transplant therapeutics market is segmented into geriatric, adult, pediatric
On the basis of end users, the Middle East and Africa lung transplant therapeutics market is segmented into hospitals, transplant centers, specialty centers, and others
Market Players:
Some of the key market players in the Middle East and Africa lung transplant therapeutics market are listed below:
Bridge to Life Ltd
Viatris Inc.
BioLife Solutions
Pfizer Inc.
F.Hoffmann-La Roche Ltd.
Panacea Biotec Ltd.
Accord-UK Ltd
Novartis AG
Hikma Pharmaceuticals PLC
Dr. Reddys Laboratories Ltd.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.